Skeletal muscle MicroRNAs: Their diagnostic and therapeutic potential in human muscle diseases

Journal of Neuromuscular Diseases

Volumn 2, Issue 1, 2015, Pages 1-11

  Alexander, Matthew S ^a,b   Kunkel, Louis M ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

Biomarker; Dystrophy; MicroRNA; Muscle disease; Skeletal muscle; Therapy

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; MICRORNA; MICRORNA 133A; MICRORNA 199A; MICRORNA 206; MICRORNA 21; MICRORNA 31; MICRORNA 378A; MIRAVIRSEN; UNCLASSIFIED DRUG;

CLINICAL EFFECTIVENESS; DISEASE COURSE; DNA SEQUENCE; DUCHENNE MUSCULAR DYSTROPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MICRORNA INHIBITION; MOLECULAR THERAPY; MOLECULARLY TARGETED THERAPY; NEUROMUSCULAR DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE;

EID: 84949091237     PISSN: 22143599     EISSN: 22143602     Source Type: Journal    
DOI: 10.3233/JND-140058     Document Type: Review

References (104)

1. Lee, R. C., Feinbaum, R. L., Ambros, V. The C. elegans heterochronic gene lin-4 encodes smallRNAs with antisense complementarity to lin-14. Cell. 1993; 75(5): p. 843-854.
2. Lagos-Quintana, M., et al. Identification of Tissue-Specific MicroRNAs from Mouse. Current Biology. 2002; 12(9): p. 735-739.
3. Lagos-Quintana, M., et al. Identification of Novel Genes Coding for Small Expressed RNAs. Science. 2001; 294(5543): p. 853-858.
4. LAGOS-QUINTANA, M., et al. New microRNAs from mouse and human. RNA. 2003; 9(2): p. 175-179.
5. Bartel, D. P. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell. 2004; 116(2): p. 281-297.
6. Li, L., et al. Computational approaches for microRNA studies: a review. Mammalian Genome. 2010; 21(1-2): p. 1-12.
7. Rajewsky, N. N.D. Socci. Computational identification of microRNA targets. Developmental Biology. 2004; 267(2): p. 529-535.
8. Kiriakidou, M., et al. A combined computationalexperimental approach predicts human microRNA targets. Genes & Development. 2004; 18(10): p. 1165-1178.
9. Bartel, D. P. MicroRNAs: Target Recognition and Regulatory Functions. Cell. 2009; 136(2): p. 215-233.
10. Lim, L. P., et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433(7027): p. 769-773.
11. Thai, T.-H., et al. Regulation of the Germinal Center Response by MicroRNA-155. Science. 2007; 316(5824): p. 604-608.
12. Ventura, A., et al. Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17-92 Family ofmiRNA Clusters. Cell. 2008; 132(5): p. 875-886.
13. van Rooij, E., et al. Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA. Science. 2007; 316(5824): p. 575-579.
14. Zhao, Y., Samal, E., Srivastava, D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005; 436(7048): p. 214-220.
15. Chen, J.-F., et al. The role of microRNA-1 and microRNA- 133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006; 38(2): p. 228-233.
16. Eisenberg, I., et al. Distinctive patterns of microRNAexpression in primary muscular disorders. Proceedings of the National Academy of Sciences. 2007; 104(43): p. 17016- 17021.
17. Cacchiarelli, D., et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Molecular Medicine. 2011; 3(5): p. 258-265.
18. Zaharieva, I. T., et al. Dystromirs as Serum Biomarkers for Monitoring the Disease Severity in Duchenne Muscular Dystrophy. PLoS ONE. 2013; 8(11): p. e80263.
19. Roberts, T. C., et al. Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover. Nucleic Acids Research. 2013.
20. Calway, T., Kim, G. H. Harnessing the Therapeutic Potential of MicroRNAs for Cardiovascular Disease. Journal of Cardiovascular Pharmacology and Therapeutics. 2014.
21. Monroig, P. d. C., et al. Small molecule compounds targeting miRNAs for cancer therapy. Advanced Drug Delivery Reviews. (0).
22. Janssen, H. L. A., et al. Treatment of HCV Infection by Targeting MicroRNA. New England Journal of Medicine. 2013; 368(18): p. 1685-1694.
23. Liu, N., et al. microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. The Journal of Clinical Investigation. 2012; 122(6): p. 2054-2065.
24. Miyazaki, Y., et al. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med. 2012; 18(7): p. 1136-1141.
25. Alexander, M. S., et al. MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms. The Journal of Clinical Investigation. 2014; 124(6): p. 2651-2667.
26. Ardite, E., et al. PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. The Journal of Cell Biology. 2012; 196(1): p. 163-175.
27. Sharma, M., et al. Mega roles of microRNAs in regulation of skeletal muscle health and disease. Frontiers in Physiology. 2014; 5.
28. Hoffman, E. P., Brown, R. H., Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987; 51: p. 919 - 928.
29. Cacchiarelli, D., et al. MicroRNAs Involved in Molecular Circuitries Relevant for the Duchenne Muscular Dystrophy Pathogenesis Are Controlled by the Dystrophin/nNOS Pathway. Cell metabolism. 2010; 12(4): p. 341-351.
30. Townley-Tilson, W. H. D., Callis, T. E., Wang, D. MicroRNAs 1. 133, and 206: Critical factors of skeletal and cardiac muscle development, function, and disease. The International Journal of Biochemistry & Cell Biology. 2010; 42(8): p. 1252-1255.
31. Sempere, L., et al. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biology. 2004; 5(3): p. R13.
32. McCarthy, J. J. MicroRNA-206: The skeletal musclespecific myomiR. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms. 2008; 1779(11): p. 682-691.
33. Cazzella, V., et al. Exon 45 Skipping Through U1-snRNA Antisense Molecules Recovers the Dys-nNOS Pathway and Muscle Differentiation in Human DMD Myoblasts. Mol Ther. 2012; 20(11): p. 2134-2142.
34. Roberts, T. C., et al. Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy. Mol Ther Nucleic Acids. 2012; 1: p. e39.
35. Greco, S., et al. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. The FASEB Journal. 2009; 23(10): p. 3335-3346.
36. Mizuno, H., et al. Identification of Muscle-Specific MicroRNAs in Serum of Muscular Dystrophy Animal Models: Promising Novel Blood-Based Markers for Muscular Dystrophy. PLoS ONE. 2011; 6(3): p. e18388.
37. Li, X., et al. Circulating Muscle-specific miRNAs in Duchenne Muscular Dystrophy Patients. Mol Ther Nucleic Acids. 2014; 3: p. e177.
38. Cacchiarelli, D., et al. miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy. EMBO Rep. 2011; 12(2): p. 136-141.
39. Alexander, M. S., et al. MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation. Cell Death Differ. 2013; 20(9): p. 1194-1208.
40. Alexander, M., et al. Regulation of DMD pathology by an ankyrin-encoded miRNA. Skeletal Muscle. 2011; 1(1): p. 27.
41. Wei, Y., et al. Multifaceted roles of miR-1s in repressing the fetal gene program in the heart. Cell Res. 2014; 24(3): p. 278-292.
42. Heidersbach, A., et al. microRNA-1 regulates sarcomere formation and suppresses smooth muscle gene expression in the mammalian heart. Elife. 2013; 2.
43. Liu, N., et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes & Development. 2008; 22(23): p. 3242-3254.
44. Wystub, K., et al. miR-1/133a Clusters Cooperatively Specify the Cardiomyogenic Lineage by Adjustment of Myocardin Levels during Embryonic Heart Development. PLoS Genet. 2013; 9(9): p. e1003793.
45. McCarthy, J. J., Esser, K. A., Andrade, F. H. MicroRNA- 206 is overexpressed in the diaphragm but not the hindlimb muscle of mdx mouse. Am J Physiol Cell Physiol. 2007; 293(1): p. C451-457.
46. Hu, J., et al. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy. Journal of Neurochemistry. 2014; 129(5): p. 877-883.
47. Williams, A. H., et al. MicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in Mice. Science. 2009; 326(5959): p. 1549-1554.
48. Liu, G., et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. The Journal of Experimental Medicine. 2010; 207(8): p. 1589-1597.
49. Ghosh, A. K., Vaughan, D. E. PAI-1 in tissue fibrosis. Journal of Cellular Physiology. 2012; 227(2): p. 493-507.
50. Hatley, M. E., et al. Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21. Cancer Cell. 2010; 18(3): p. 282-293.
51. Ma, X., et al. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proceedings of the National Academy of Sciences. 2011; 108(25): p. 10144-10149.
52. Thum, T., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456(7224): p. 980-984.
53. Patrick, D. M., et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. The Journal of Clinical Investigation. 2010; 120(11): p. 3912-3916.
54. Zhang, X.-Y., et al. Induction of Thoracic Aortic Remodeling by Endothelial-Specific Deletion of MicroRNA-21 in Mice. PLoS ONE. 2013; 8(3): p. e59002.
55. Medina, P. P., Nolde, M., Slack, F. J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010; 467(7311): p. 86-90.
56. Acuña, M. J., et al. Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-κ signalling. Human Molecular Genetics. 2014; 23(5): p. 1237-1249.
57. Deutekom, J. C. T. V., et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2kb tandemly repeated unit. Human Molecular Genetics. 1993; 2(12): p. 2037-2042.
58. Hewitt, J. E., et al. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystropothhy. Human Molecular Genetics. 1994; 3(8): p. 1287-1295.
59. Lemmers, R. J. L. F., et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet. 2012; 44(12): p. 1370-1374.
60. Cheli, S., et al. Expression Profiling of FSHD-1 and FSHD-2 Cells during Myogenic Differentiation Evidences Common and Distinctive Gene Dysregulation Patterns. PLoS ONE. 2011; 6(6): p. e20966.
61. Winokur, S. T., et al. Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Human Molecular Genetics. 2003; 12(22): p. 2895-2907.
62. Harafuji, N., et al. miR-411 is up-regulated in FSHD myoblasts and suppresses myogenic factors. Orphanet Journal of Rare Diseases. 2013; 8(1): p. 55.
63. Dmitriev, P., et al. Defective Regulation of MicroRNA Target Genes in Myoblasts from Facioscapulohumeral Dystrophy Patients. Journal of Biological Chemistry. 2013; 288(49): p. 34989-35002.
64. Matsuzaka, Y., et al. Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy. Environmental Health and Preventive Medicine. 2014: p. 1-7.
65. Colangelo, V., et al. Next-Generation Sequencing Analysis of MiRNA Expression in Control and FSHD Myogenesis. PLoS ONE. 2014; 9(10): p. e108411.
66. Cabianca, Daphne S., et al. A Long ncRNA Links Copy Number Variation to a Polycomb/Trithorax Epigenetic Switch in FSHD Muscular Dystrophy. Cell. 2012; 149(4): p. 819-831.
67. Tsumagari, K., et al. Gene expression during normal and FSHD myogenesis. BMC Medical Genomics. 2011; 4(1): p. 67.
68. Yao, Z., et al. DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle. Human Molecular Genetics. 2014; 23(20): p. 5342-5352.
69. Vanderplanck, C., et al. The FSHD Atrophic Myotube Phenotype Is Caused by DUX4 Expression. PLoS ONE. 2011; 6(10): p. e26820.
70. Holmberg, J., et al. Laminin -2 chain-deficiency is associated with microRNA deregulation in skeletal muscle and plasma. Frontiers in Aging Neuroscience. 2014; 6.
71. Rosales, X. Q., et al. Impaired regeneration in LGMD2A supported by increased PAX7-positive satellite cell content and muscle-specific microrna dysregulation. Muscle & Nerve. 2013; 47(5): p. 731-739.
72. Richard, I., et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell. 1995; 81(1): p. 27-40.
73. Vignier, N., et al. Distinctive Serum miRNA Profile in Mouse Models of Striated Muscular Pathologies. PLoS ONE. 2013; 8(2): p. e55281.
74. Liquori, C. L., et al. Myotonic Dystrophy Type 2 Caused by a CCTG Expansion in Intron 1 of ZNF9. Science. 2001; 293(5531): p. 864-867.
75. Brook, J. D., et al. Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992; 68(4): p. 799-808.
76. Perbellini, R., et al. Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscular Disorders. 2011; 21(2): p. 81-88.
77. Greco, S., et al. Deregulated MicroRNAs in Myotonic Dystrophy Type 2. PLoS ONE. 2012; 7(6): p. e39732.
78. Cardinali, B., et al. Microrna-221 and Microrna-222 Modulate Differentiation and Maturation of Skeletal Muscle Cells. PLoS ONE. 2009; 4(10): p. e7607.
79. Carrer, M., et al. Control of mitochondrial metabolism and systemic energy homeostasis by microRNAs 378 and 378. Proceedings of the National Academy of Sciences. 2012; 109(38): p. 15330-15335.
80. Rau, F., et al. Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nat Struct Mol Biol. 2011; 18(7): p. 840-845.
81. Koshkin, A. A., et al. LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron. 1998; 54(14): p. 3607-3630.
82. Nielsen, C. B., et al. The Solution Structure of a Locked Nucleic Acid (LNA) Hybridized to DNA. Journal of Biomolecular Structure and Dynamics. 1999; 17(2): p. 175-191.
83. Hutvágner, G., et al. Sequence-Specific Inhibition of Small RNA Function. PLoS Biol. 2004; 2(4): p. e98.
84. Krutzfeldt, J., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005; 438(7068): p. 685-689.
85. Ørom, U. A., Kauppinen, S., Lund, A. H. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene. 2006; 372(0): p. 137-141.
86. Ebert, M. S., Neilson, J. R., Sharp, P. A. MicroRNAsponges: competitive inhibitors of small RNAs in mammalian cells. Nat Meth. 2007; 4(9): p. 721-726.
87. Tay, F. C., et al. Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells. Advanced Drug Delivery Reviews. 2014(0).
88. Chen, L., Chen, L., Zhang, K., Zhang, K., Shi, Z., Shi, Z., Zhang, A., Zhang, A., Jia, Z., Jia, Z., Wang, G., Wang, G., Pu, P., Pu, P., Kang, C., Kang, C., Han, L., Han, L. A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo. Oncology Reports. 2014; 31(4): p. 1573-1580.
89. Winbanks, C. E., et al. miR-206 Represses Hypertrophy of Myogenic Cells but Not Muscle Fibers via Inhibition of HDAC4. PLoS ONE. 2013; 8(9): p. e73589.
90. Tan, S.-B., et al. Small Molecule Inhibitor of Myogenic microRNAs Leads to a Discovery of miR-221/222-myoDmyomiRs Regulatory Pathway. Chemistry&Biology. 2014; 21(10): p. 1265-1270.
91. da Costa Martins, P. A., et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol. 2010; 12(12): p. 1220-1227.
92. Bernardo, B. C., et al. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. The FASEB Journal. 2014.
93. Kota, J., et al. Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model. Cell, 2009; 137(6): p. 1005-1017.
94. Yang, X., et al. Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microrna cluster. Hepatology. 2010; 52(6): p. 1877-1887.
95. Quattrocelli, M., et al. Long-Term miR-669a Therapy Alleviates Chronic Dilated Cardiomyopathy in Dystrophic Mice. Journal of the American Heart Association. 2013; 2(4).
96. Grimm, D., et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006; 441(7092): p. 537-541.
97. Odom, G. L., et al. Microutrophin Delivery Through rAAV6Increases Lifespan and ImprovesMuscle Function in Dystrophic Dystrophin/Utrophin-deficient Mice. Mol Ther. 2008; 16(9): p. 1539-1545.
98. Lai, Y., et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. The Journal of Clinical Investigation. 2009; 119(3): p. 624-635.
99. Lai, Y., et al. Partial restoration of cardiac function with -PDZ nNOS in aged mdx model of Duchenne cardiomyopathy. Human Molecular Genetics. 2014; 23(12): p. 3189-3199.
100. Charan, R. A., et al. Adeno-associated virus serotype 8 (AAV8) delivery of recombinant A20 to skeletal muscle reduces pathological activation of nuclear factor (NF)-κB in muscle of mdx mice. Molecular Medicine. 2012; 18: p. 1527-1535.
101. Pantazi, A., Zovoilis, A. Vector-Free Methods for Manipulating miRNA Activity In Vitro and In Vivo, in MicroRNA Protocols, S.-Y. Ying, Editor. 2013, Humana Press. p. 231-245.
102. Wallace, L. M., et al. RNA Interference Inhibits DUX4- induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy. Mol Ther. 2012; 20(7): p. 1417-1423.
103. Liu, N., et al. Mice lacking microRNA 133a develop dynamin 2-dependent centronuclear myopathy. The Journal of Clinical Investigation. 2011; 121(8): p. 3258-3268.
104. Clop, A., et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet. 2006; 38(7): p. 813-818.